Vir Biotechnology (VIR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

VIR · Stock Price

USD 9.27+4.19 (+82.30%)

Market Cap: $1.6B

Historical price data

Market Cap: $1.6BPipeline: 27 drugs (5 Phase 3)Patents: 10Founded: 2016HQ: San Francisco, United States

Sector Ranking#91 in Biologics / Biosimilars #9 in Immunotherapy / Immuno-Oncology

Overview

Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.

Infectious DiseasesOncology

Technology Platform

Vir's core technologies are a next-generation antibody platform for rapid discovery/engineering of antibodies for infectious diseases, and the exclusive PRO-XTEN® protease-releasable masking technology designed to improve the therapeutic index of potent biologics in oncology and infectious disease.

Pipeline

27

27 drugs in pipeline5 in Phase 3

Drug	Indication	Stage
Tobevibart + Elebsiran	Viral Hepatitis	Phase 3
VIR-7831 + Placebo + Remdesivir	COVID-19	Phase 3
Tobevibart + Elebsiran + Bulevirtide	Viral Hepatitis	Phase 3
sotrovimab + sotrovimab + sotrovimab + sotrovimab + Sotrovim...	Covid19	Phase 3
VIR-7831 (sotrovimab) + Placebo	Covid19	Phase 2/3

Funding History

4

Total raised:$993M

PIPE$450MSoftBank Vision FundFeb 15, 2021

IPO$143MUndisclosedOct 15, 2019

Series B$250MARCH Venture PartnersDec 15, 2018

Series A$150MARCH Venture PartnersOct 15, 2017

Opportunities

The lead Phase 3 program in chronic hepatitis delta (CHD) addresses a severe disease with no approved U.S.

therapies, representing a major near-term commercial opportunity.

The strategic collaboration with Astellas on the masked T-cell engager VIR-5500 accelerates its development in the large prostate cancer market and validates the oncology platform.

Risk Factors

The company faces binary clinical risk from its pivotal Phase 3 ECLIPSE trial in CHD.

Intense competition in both infectious diseases and oncology, alongside the high costs of late-stage development, pose significant commercial and financial challenges.

Competitive Landscape

Vir is a leader in CHD development but faces intense competition in prostate cancer from established therapies and novel modalities. Its differentiation lies in its antibody engineering speed and the PRO-XTEN® masking technology's potential to improve the safety profile of potent immunotherapies.